接受抗逆转录病毒治疗的HIV感染者中第一年低水平病毒血症与后续病毒抑制未达标的相关性——中国云南省德宏傣族景颇族自治州，2008 - 2021年
Associations of First-Year Low-Level Viremia with Subsequent Viral Non-Suppression in People Living with HIV on Antiretroviral Therapy - Dehong Dai and Jingpo Autonomous Prefecture, Yunnan Province, China, 2008-2021.
作者信息
Yu Hailiang, Ye Runhua, Cao Dongdong, Cao Yanfen, Shi Yun, Xiao Guifang, Li Pinyin, Feng Yanling, Wei Hua, Sun Jinting, Duan Song, Yang Yuecheng, Jin Cong
机构信息
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Dehong Prefecture, Yunnan Province, China.
出版信息
China CDC Wkly. 2025 Jan 10;7(2):45-52. doi: 10.46234/ccdcw2025.010.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Human immunodeficiency virus (HIV) low-level viremia (LLV) during antiretroviral therapy (ART) occurs frequently in Dehong Dai and Jingpo Autonomous Prefecture, Yunnan Province.
WHAT IS ADDED BY THIS REPORT?: Among people living with HIV who achieved virological success [viral load (VL) <1,000 copies/mL] after initiating ART in Dehong Prefecture, Southwest China, 17.6% experienced first-year LLV of 50-999 copies/mL First-year LLV emerged as an independent risk factor for subsequent viral non-suppression compared with participants maintaining first-year VL <50 copies/mL.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Enhanced monitoring and interventions for early LLV occurrence during the first year of ART are essential, including adherence education and timely VL testing.
关于该主题已知的信息有哪些？：在云南省德宏傣族景颇族自治州，接受抗逆转录病毒治疗（ART）期间，人类免疫缺陷病毒（HIV）低水平病毒血症（LLV）频繁发生。
本报告新增了哪些内容？：在中国西南部德宏州开始接受ART治疗后实现病毒学成功[病毒载量（VL）<1000拷贝/毫升]的HIV感染者中，17.6%的人在第一年出现了50 - 999拷贝/毫升的LLV。与第一年VL维持在<50拷贝/毫升的参与者相比，第一年出现LLV成为随后病毒抑制失败的一个独立危险因素。
对公共卫生实践有何启示？：在ART治疗的第一年，加强对早期LLV发生情况的监测和干预至关重要，包括依从性教育和及时进行VL检测。
Zotero 插件